Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

100.24USD
30 Sep 2016
Change (% chg)

$-0.34 (-0.34%)
Prev Close
$100.58
Open
$101.34
Day's High
$101.34
Day's Low
$96.56
Volume
398,234
Avg. Vol
333,394
52-wk High
$110.48
52-wk Low
$29.51

TSRO.OQ

Chart for TSRO.OQ

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $5,148.90
Shares Outstanding(Mil.): 51.37
Dividend: --
Yield (%): --

Financials

  TSRO.OQ Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -6.86 -- --
ROI: -93.60 -0.29 13.93
ROE: -154.75 -2.99 14.84

BRIEF-Tesaro and Zai Lab announce collaboration, development and license agreement

* Tesaro and zai lab announce collaboration, development and license agreement

Sep 29 2016

BRIEF-Tesaro gets FDA fast track designation for niraparib

* Tesaro receives FDA fast track designation for niraparib and initiates rolling NDA submission

Sep 12 2016

BRIEF-Tesaro Q2 loss per share $1.28

* Q2 loss per share $1.28 Source text for Eikon: (http://bit.ly/2axcOJk) Further company coverage:

Aug 04 2016

BRIEF-Engot and Tesaro present positive data from ovarian cancer drug

* Engot and Tesaro partnership generates positive data from engot-ov16/nova phase 3 trial

Jul 08 2016

BRIEF-Tesaro files for mixed shelf offering - SEC filing

* Says files for mixed shelf offering with the U.S. SEC; size undisclosed - SEC filing Source: (http://1.usa.gov/295fkJh ) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 30 2016

BRIEF-Tesaro Inc says commenced an underwritten public offering of $300 mln of its common stock

* Tesaro Inc says has commenced an underwritten public offering of $300 million of its common stock Source text for Eikon: Further company coverage: )

Jun 30 2016

Tesaro's ovarian cancer drug study succeeds, shares soar

Tesaro Inc said its experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares to a record high.

Jun 29 2016

UPDATE 2-Tesaro's ovarian cancer drug study succeeds, shares soar

* Shares of rival Clovis Oncology also rise (Adds details; analyst comments)

Jun 29 2016

Tesaro's ovarian cancer drug shows benefit in late-stage trial

June 29 Tesaro Inc said its ovarian cancer drug met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares up 69 percent in premarket trading.

Jun 29 2016

BRIEF-Steven Cohen reports 5.3 percent passive stake in Tesaro Inc

* Steven Cohen reports 5.3 percent passive stake in Tesaro Inc as of May 9 - Sec filing Source text: http://1.usa.gov/1WmJHft Further company coverage:

May 10 2016

Earnings vs. Estimates